Deutsche Bank
HRTX icon

Deutsche Bank’s Heron Therapeutics HRTX Stock Holding History

Deutsche Bank’s Portfolio HRTX Stock Details HRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$74.5K Hold
93,081
– – ﹤0.01% 3364
2025
Q4 		$121K Buy
93,081
+7,923
+9% +$9.78K ﹤0.01% 3233
2025
Q3 		$107K Buy
85,158
+17,429
+26% +$27.6K ﹤0.01% 3302
2025
Q2 		$140K Sell
67,729
-17,881
-21% -$36.5K ﹤0.01% 3122
2025
Q1 		$188K Buy
85,610
+25,824
+43% +$50.1K ﹤0.01% 2976
2024
Q4 		$91.5K Hold
59,786
– – ﹤0.01% 3310
2024
Q3 		$119K Buy
59,786
+28,470
+91% +$68K ﹤0.01% 3154
2024
Q2 		$110K Sell
31,316
-12,549
-29% -$38.6K ﹤0.01% 3080
2024
Q1 		$122K Sell
43,865
-1,686
-4% -$4.24K ﹤0.01% 3074
2023
Q4 		$77.4K Hold
45,551
– – ﹤0.01% 3329
2023
Q3 		$46.9K Hold
45,551
– – ﹤0.01% 3421
2023
Q2 		$52.8K Sell
45,551
-21,588
-32% -$38.5K ﹤0.01% 3467
2023
Q1 		$101K Buy
67,139
+16,427
+32% +$41.1K ﹤0.01% 3318
2022
Q4 		$127K Buy
50,712
+689
+1% +$2.22K ﹤0.01% 3216
2022
Q3 		$212K Sell
50,023
-5,144
-9% -$20.1K ﹤0.01% 2911
2022
Q2 		$154K Sell
55,167
-138,928
-72% -$558K ﹤0.01% 3309
2022
Q1 		$1.11M Sell
194,095
-194,535
-50% -$1.42M ﹤0.01% 2277
2021
Q4 		$3.55M Sell
388,630
-140,710
-27% -$1.44M ﹤0.01% 1636
2021
Q3 		$5.66M Buy
529,340
+8,655
+2% +$105K ﹤0.01% 1433
2021
Q2 		$8.08M Buy
520,685
+102,082
+24% +$1.62M ﹤0.01% 1277
2021
Q1 		$6.79M Sell
418,603
-272,725
-39% -$4.86M ﹤0.01% 1393
2020
Q4 		$14.6M Buy
691,328
+84,027
+14% +$1.46M 0.01% 892
2020
Q3 		$9M Buy
607,301
+14,060
+2% +$219K 0.01% 1006
2020
Q2 		$8.73M Buy
593,241
+172,290
+41% +$2.83M 0.01% 1032
2020
Q1 		$4.94M Sell
420,951
-102,361
-20% -$1.92M ﹤0.01% 1248
2019
Q4 		$12.3M Buy
523,312
+40,858
+8% +$904K 0.01% 997
2019
Q3 		$8.92M Sell
482,454
-45,187
-9% -$832K 0.01% 1126
2019
Q2 		$9.81M Buy
527,641
+168,971
+47% +$3.38M 0.01% 1391
2019
Q1 		$8.76M Buy
358,670
+277,263
+341% +$7.26M 0.01% 1473
2018
Q4 		$2.11M Sell
81,407
-691,123
-89% -$19M ﹤0.01% 2361
2018
Q3 		$24.5M Sell
772,530
-171,405
-18% -$6.38M 0.01% 1019
2018
Q2 		$36.7M Buy
943,935
+200,218
+27% +$6.37M 0.02% 816
2018
Q1 		$20.5M Buy
743,717
+302,855
+69% +$6.87M 0.01% 1100
2017
Q4 		$7.98M Buy
440,862
+39,336
+10% +$641K 0.01% 1661
2017
Q3 		$6.48M Sell
401,526
-235,248
-37% -$3.69M ﹤0.01% 1744
2017
Q2 		$8.82M Sell
636,774
-60,643
-9% -$878K 0.01% 1494
2017
Q1 		$10.5M Buy
697,417
+441,883
+173% +$6.12M 0.01% 1235
2016
Q4 		$3.35M Buy
255,534
+157,445
+161% +$2.47M ﹤0.01% 1927
2016
Q3 		$1.69M Sell
98,089
-45,741
-32% -$849K ﹤0.01% 2470
2016
Q2 		$2.59M Buy
143,830
+77,891
+118% +$1.52M ﹤0.01% 2216
2016
Q1 		$1.25M Sell
65,939
-3,709
-5% -$73.2K ﹤0.01% 2673
2015
Q4 		$1.86M Sell
69,648
-33,707
-33% -$901K ﹤0.01% 2486
2015
Q3 		$2.52M Sell
103,355
-61,848
-37% -$2.06M ﹤0.01% 2326
2015
Q2 		$5.15M Buy
165,203
+45,947
+39% +$864K ﹤0.01% 1783
2015
Q1 		$1.73M Buy
119,256
+7,472
+7% +$84.2K ﹤0.01% 2538
2014
Q4 		$1.12M Buy
111,784
+24,358
+28% +$199K ﹤0.01% 3130
2014
Q3 		$726K Buy
87,426
+4,950
+6% +$46.1K ﹤0.01% 3240
2014
Q2 		$1.01M Buy
82,476
+79,263
+2,467% +$947K ﹤0.01% 2932
2014
Q1 		$44K Buy
+3,213
New +$42.9K ﹤0.01% 4595

Other funds holding HRTX

RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
CC
Clearline Capital New York $1.93B AUM 38.13% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
VCIM
Velan Capital Investment Management Alpharetta, Georgia $160M AUM 517.12% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
TC
Tejara Capital London, United Kingdom $303M AUM 5.43% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
PCM
Palisade Capital Management Fort Lee, New Jersey $3B AUM 14% 1-Year Est. Return

Deutsche Bank's HRTX Position: Q1 2026 in Review

Deutsche Bank held its Heron Therapeutics (HRTX) position steady in Q1 2026 at 93,081 shares worth $74.5K. The position accounts for ﹤0.01% of the portfolio, ranked #3364.

Deutsche Bank first reported a position in HRTX in Q1 2014 and has held it in 49 quarters since. The position peaked at $36.7M in Q2 2018. 167 funds tracked by Wall St. Rank hold HRTX as of Q1 2026.

  • Deutsche Bank held 93,081 shares of Heron Therapeutics worth $74.5K as of Q1 2026.
  • Deutsche Bank left its Heron Therapeutics share count unchanged in Q1 2026.
  • Heron Therapeutics made up ﹤0.01% of Deutsche Bank's portfolio in Q1 2026, its #3364 holding.
  • Deutsche Bank first reported a position in Heron Therapeutics in Q1 2014 and has held it in 49 quarters since.
  • Deutsche Bank's Heron Therapeutics position peaked at $36.7M in Q2 2018.
  • 167 funds tracked by Wall St. Rank held Heron Therapeutics as of Q1 2026.

Based on Deutsche Bank's 13F filing for Q1 2026, filed 6 May 2026.